1-4 of 4
James D. Hilger
Close
Sort by
Journal Articles

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Clinical Trials & Observations
Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Munoz, Alessandra Tedeschi, Andrew W. Roberts, John F. Seymour, Siminder Kaur Atwal, Yiling Yu, William Novotny, Eric Holmgren, Ziwen Tan, James D. Hilger, Jane Huang, Constantine S. Tam
Journal: Blood
Blood (2020) 136 (18): 2027–2037.
https://doi.org/10.1182/blood.2020006449
Published: 2020
Includes: Supplemental data
Journal Articles

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard Klein, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD
Journal: Blood
Blood (2013) 122 (21): 3218.
https://doi.org/10.1182/blood.V122.21.3218.3218
Published: 2013
Journal Articles

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

James R. Berenson, MD, James D. Hilger, Ph.D., Robert Dichmann, MD, Dipti Patel-Donnelly, MD, Ralph V. Boccia, MD, Alberto Bessudo, MD, Laura V. Stampleman, MD, Donald S. Gravenor, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD
Journal: Blood
Blood (2012) 120 (21): 4063.
https://doi.org/10.1182/blood.V120.21.4063.4063
Published: 2012
Journal Articles

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard M. Klein, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD
Journal: Blood
Blood (2012) 120 (21): 2979.
https://doi.org/10.1182/blood.V120.21.2979.2979
Published: 2012